The indirect impact of COVID-19 large-scale containment measures on the incidence of community-acquired pneumonia in the elderly: a region-wide population-based study in Tuscany, Italy by Lastrucci, Vieri et al.
International Journal of Infectious Diseases 109 (2021) 182–188 
Contents lists available at ScienceDirect 
International Journal of Infectious Diseases 
journal homepage: www.elsevier.com/locate/ijid 
The indirect impact of COVID-19 large-scale containment measures on 
the incidence of community-acquired pneumonia in older people: a 
region-wide population-based study in Tuscany, Italy 
Vieri Lastrucci a , b , ∗, Guglielmo Bonaccorsi b , Silvia Forni c , Sara D’Arienzo c , Letizia Bachini c , 
Sonia Paoli d , Chiara Lorini b , Fabrizio Gemmi c 
a Epidemiology Unit, Meyer Children’s University Hospital, Viale Gaetano Pieraccini 24, 50139, Florence, Italy 
b Department of Health Sciences, University of Florence, Viale GB Morgagni 48, 50134, Florence, Italy 
c Quality and Equity Unit, Regional Health Agency of Tuscany, Via Pietro Dazzi 1, 50141, Florence, Italy 
d Medical Specialization School of Hygiene and Preventive Medicine, University of Florence, 50134 Florence, Italy 
a r t i c l e i n f o 
Article history: 
Received 16 April 2021 
Revised 12 June 2021 








a b s t r a c t 
Objective: To evaluate the indirect effect of COVID-19 large-scale containment measures on the incidence 
of community-acquired pneumonia (CAP) in older people during the first epidemic wave of COVID-19 in 
Tuscany, Italy. 
Methods: A population-based study was carried out on data from the Tuscany healthcare system. The 
outcome measures were: hospitalization rate for CAP, severity of CAP hospitalizations, and outpatient 
consumption of antibacterials for CAP in people aged 65 and older. Outcomes were compared between 
corresponding periods in 2020 (week 1 to 27) and previous years. 
Results: Compared with the average of the corresponding periods in the previous 3 years, significant 
reductions in weekly hospitalization rates for CAP were observed from the week in which the national 
containment measures were imposed (week 10) until the end of the first COVID-19 wave in July (week 
27). There was also a significant decrease in outpatient consumption in all antibacterial classes for CAP. 
Conclusions: The implementation of large-scale COVID-19 containment measures likely reduced the inci- 
dence of CAP in older people during the first wave of the COVID-19 pandemic in Tuscany, Italy. Consider- 
ing this indirect impact of pandemic containment measures on respiratory tract infections may improve 
the planning of health services during a pandemic in the future. 
© 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 

























Community-acquired pneumonia (CAP) is one of the lead- 
ng causes of morbidity and mortality among all age groups, 
nd especially in older adults. The most commonly identified 
athogens of pneumonia in older people are bacteria, such as 
treptococcus pneumoniae and Haemophilus influenza, and viruses 
 Bartlett and Mundy, 1995 ; Feldman, 1999 ; Fernandez-Sabé, 2003 ). 
hese pathogens are mainly transmitted person-to-person via the 
espiratory route. 
SARS-CoV-2 was identified in January 2020 as the etiological 
gent of COVID-19, an unusual viral pneumonia firstly observed in ∗ Corresponding author. (V. Lastrucci). 




201-9712/© 2021 The Authors. Published by Elsevier Ltd on behalf of International Socie
 http://creativecommons.org/licenses/by/4.0/ ) uhan Province, China, at the end of 2019 ( Shereen et al., 2020 ;
orbalenya et al., 2020 , World Health Organization, 2020a ). Since 
hen, COVID-19 rapidly spread across the globe and was declared 
y the World Health Organization (WHO) as a global pandemic on 
1 March 2020 ( World Health Organization, 2020b ). 
Since the COVID-19 outbreak, large-scale measures to prevent 
isease transmission have been implemented worldwide. Gov- 
rnment responses have included the prohibition of large-scale 
vents, stay-at-home orders and national/local lockdown; further- 
ore, people were asked to wear face masks, respect physical dis- 
ancing and take other simple precautions such as handwashing, 
eeping rooms well ventilated, avoiding gatherings, and coughing 
nto a bent elbow or tissue. 
If effectively implemented, these measures may have led to 
 reduction of the spread of other respiratory infectious dis- ty for Infectious Diseases. This is an open access article under the CC BY license 





















































































































ases at the community level. However, evidence from epidemi- 
logic studies has begun to appear only recently as contain- 
ent measures implemented at such a stringent, persistent and 
idespread level are unprecedented in modern times ( Wu et al., 
020 ; Sullivan et al., 2020 ; Kuo et al., 2021 ; Yamamoto et al.,
020 ; Chan et al., 2020 ; Chiu et al., 2020 ). To accurately evalu-
te the potential reduction of the burden of respiratory infectious 
iseases, this phenomenon needs to be measured in large and 
ell-defined populations. Furthermore, large time frames—such as 
 whole intra-epidemic period—need to be considered as the SARS- 
oV-2 infection in itself has the potential for increasing the in- 
idence of bacterial pneumonia given that viral respiratory infec- 
ions are usually associated with an increased risk of subsequent 
acterial infections ( Morens et al., 2008 ; Morens and Fauci 2007 ; 
olter et al., 2014 ; Salomon et al., 2020 ). 
Thus, to date, the impact of a viral respiratory infection pan- 
emic and the related large-scale control measures on the burden 
f respiratory infectious diseases at the community level remains 
nclear. However, its estimation would have important implica- 
ions for health services planning and preparedness during a pan- 
emic. Therefore, our study aims to evaluate the extent to which 
arge-scale containment strategies implemented during the COVID- 
9 pandemic have influenced the incidence of CAP in the Tuscany 
egion (Italy) during the first pandemic wave (February–July 2020). 
Tuscany is a region in central Italy with an area of approxi- 
ately 23 0 0 0 square kilometers and a population of more than 
.7 million. Italy was one of the first Western countries severely 
ffected by the COVID-19 pandemic. The first autochthonous Ital- 
an case was identified on 21 February 2020, but evidence suggests 
hat SARS-CoV-2 was already circulating undetected at the end of 
019 ( La Rosa et al., 2020 ). Indeed, a study carried out by the Ital-
an Institute of Health documented the presence of the SARS-CoV- 
 in untreated wastewaters of different geographic Italian regions 
uring December 2019. In Tuscany, the first case of COVID-19 was 
bserved on 24 February 2020. During the first wave of the epi- 
emic, the Italian government imposed a 3-phase strategy to con- 
ain the circulation of SARS-CoV-2 ( Lastrucci et al., 2020 ). In the 
rst phase, from 11 March to 3 May 2020, a national lockdown 
as adopted, which included the suspension of all non-essential 
ervices and activities–including schools–and the imposition of a 
tay-at-home order banning all non-essential travel and contact 
ith others. Beside these measures, physical distancing rules and 
he obligation to wear a face mask when leaving home were in- 
roduced. These measures were effective in containing the COVID- 
9 epidemic. In the second phase, from 4 May to 3 June 2020, 
 gradual reopening of services and business was allowed, and 
ree movement was granted to all citizens within their region, but 
ovement across regions for non-essential reasons was forbidden. 
n phase 3, free movement within the whole national territory was 
estored and cinemas and theatres reopened, physical distancing 
ules and face masks remained mandatory, and schools remained 
losed until September 2020. 
ethods 
This study was conducted in accordance with the Helsinki Dec- 
aration. According to the Italian legislation (law 211/2003) and the 
egional procedures, the study does not need ethical approval as 
t is a purely observational study on routine collected anonymous 
ata. 
tudy design, population and data source 
This is a cross-sectional retrospective study based on data from 
he Tuscany public healthcare system (TPHCS). TPHCS provides 183 niversal health coverage for all Tuscany residents. TPHCS com- 
rises an extensive integrated healthcare delivery system with 38 
econdary level hospitals, 4 university teaching hospitals and ap- 
roximately 30 0 0 general practitioners, providing comprehensive 
are for more than 3.7 million residents throughout the whole re- 
ion. 
Data used for this analysis were derived from the regional 
ealthcare data system, which comprises several healthcare data 
ources. For the present study, the outpatient prescriptions and 
he inpatient hospitalizations registries were used. For the outpa- 
ient prescriptions registry, records of dispensed drugs for outpa- 
ient use are registered at the patient level. Records include pa- 
ient demographics, information on the dispensed drug (includ- 
ng active substance, Anatomical Therapeutic Chemical (ATC) code, 
rand name, formulation), date of dispensing and the number of 
ispensed packages. 
easures and statistical analyses 
The primary outcome was the hospitalization rate for CAP not 
aused by SARS-CoV-2 occurring in people aged ≥65 over the time 
rame corresponding to the entire first epidemic wave of COVID- 
9 in the Tuscany region (Week 1 to 27, 2020). In particular, the 
CD-IX-CM principal diagnosis codes registered in the hospital dis- 
harge records were used to identify CAP cases; the following ICD- 
X-CM principal diagnosis codes were considered: 4 80xx, 4 81xx, 
 82xx, 4 83xx, 4 85xx, 4 86xx, 4 870x. The outcome was measured 
y week (Monday to Sunday) and by considering 2 distinct peri- 
ds; the first from Week 1 to 9 (i.e., the COVID-19 pre-epidemic 
eriod) and the second from Week 10 to 27 (i.e., the COVID-19 
pidemic period). The hospitalization rates for CAP in 2020 were 
ompared with the average hospitalization rates for CAP occurring 
n the previous 3 years (2017–19) in the corresponding periods. 
Hospitalizations were characterized accordingly to the following 
ovariates: demographics (age and sex) and comorbidity. Comor- 
idity was measured using the Charlson Comorbidity Index (CCI) 
 Quan et al., 2011 )). Furthermore, the average hospital length of 
tay (ALOS), percentage of hospitalizations requiring the intensive 
are unit (ICU), and in-hospital mortality of patients hospitalized 
ith CAP were assessed as the secondary outcomes of the study. 
hese outcomes were used as markers of the severity of the CAP 
ospitalizations. 
In order to take into account a possible shift of care for less se- 
ere CAP cases from the hospital to outpatient settings, records of 
utpatient dispensed drugs in people aged ≥65 were assessed in 
he pre-epidemic and epidemic period of 2020 and compared with 
ata of the corresponding periods of the previous year (2019). The 
uidelines of the TPHCS for treatment of CAP in the outpatient set- 
ing are to empirically treat almost all CAP patients with antibacte- 
ials for systemic use without further testing to ascertain the etiol- 
gy. The antibacterials for systemic use indicated for the treatment 
f CAP in the outpatient settings were identified accordingly to the 
uidelines for the management of CAP in the Tuscany region and 
rom the leading international scientific societies (Tuscany Regional 
herapeutic Commission, 2017 ; Metlay et al., 2019 ; Lim et al., 
009 ). The following antibacterials for systemic use were evalu- 
ted: third generation cephalosporins (ATC code: J01DD), fluoro- 
uinolones (ATC code: J01MA), penicillins with extended-spectrum 
nd combinations of penicillins including beta-lactamase inhibitors 
ATC codes: J01CA and J01CR); and macrolides (ATC code: J01FA). 
ispensed drugs were then measured with the defined daily doses 
DDD) assigned per ATC code using the WHO Collaborating Cen- 
re for Drug Statistics Methodology ( WHO Collaborating Centre for 
rug Statistics Methodology, 2020 ). 
Percentage changes in the hospitalization rates for CAP were 
alculated for the corresponding periods of 2020 and 2017–19. Per- 
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Figure 1. A. Weekly hospitalization rates for CAP in 2017-2019 versus 2020 and relative changes in people aged 65 or older in Tuscany region 






































































entage changes in the antibacterial consumptions were calculated 
or corresponding periods of 2020 and 2019. 95% CI and the statis- 
ical significance of the percentage changes were calculated using 
he Poisson model for each period considered in the study. To com- 
are ALOS, hospitalizations requiring ICU, and in-hospital mortality 
etween 2017–2019 and 2020, age, sex, and CCI standardized ratios 
SR) were calculated. The indirect standardization was performed 
sing the patients hospitalized for CAP in 2017–19 as the standard 
opulation. For each analysis, an α level of 0.05 was considered as 
ignificant. The statistical software Stata 14 SE (StataCorp LP, Col- 
ege Station, Texas) was used for the data analyses. 
esults 
A total of 3346 new CAP hospitalizations occurred in people 
ged ≥65 in the study period (Week 1 to 27, 2020). Figure 1 shows
he weekly hospitalization rates for CAP from Week 1 to 27 of 
020, the average weekly hospitalization rates for CAP observed in 
he previous 3 years, and the weekly number of hospitalizations 
or COVID-19 occurring in the Tuscany region. In the COVID-19 pre- 
pidemic period (Week 1 to 9, 2020), the weekly hospitalization 
ates for CAP were similar to the average weekly hospitalization 
ates registered in the previous 3 years, except for the first 3 weeks 
f the years ( Figure 1 A). However, for the COVID-19 epidemic pe- 
iod (Week 10 to 27, 2020), the weekly hospitalization rates for 
AP were significantly lower than the average of the previous 3 
ears; the maximum decrease from the average weekly hospital- 
zation rates of the previous 3 years was registered in Week 22 
-46%) ( Figure 1 A). The significant decrease in the weekly hospital- 
zation rates for CAP started in Week 10—coinciding with the first 
ajor increase in the number of weekly COVID-19 hospitalizations 
from 8 to 62) and with the implementation of the first national 
ontainment measures—and persisted after the lift of the national 
ockdown (Week 23) until the end of the study period (Week 27) 
 Figure 1 A). By that time, the number of new COVID-19 hospital- 
zations had decreased to 7 ( Figure 1 B). 
Table 1 reports the characteristics of hospitalizations and hos- 
italization rates for CAP in people aged ≥65 in the COVID-19 184 pidemic period and the corresponding period in 2017–2019. The 
ospitalization rate for CAP was 190.7 per 100 000 population 
uring the COVID-19 epidemic period. Compared with the aver- 
ge in the corresponding period of the previous 3 years (2017–
9), the hospitalization rate for CAP significantly decreased in the 
OVID-19 epidemic period (-31.5%; 95% CI -36%, -27%; P < 0.001) 
see Table 1 ). The decrease in the hospitalization rate for CAP was 
imilar for men and women (-29.6% and -33.6%, respectively) and 
mong the 3 age groups considered (-30.4%, -29.1% and -34.0% for 
5–74 years, 75–84 and ≥85, respectively). 
In the pre-epidemic period, 46.1% and 9.4% of the CAP hospi- 
alizations had a CCI of 0–1 and ≥5, respectively (see Table 2 ). 
he ALOS was 9.1 days, the percentage of hospitalizations requir- 
ng the ICU was 1.5%, and in-hospital mortality was 8.6%, and there 
ere no significant differences from the same period in the previ- 
us 3 years ( Table 2 ). In the COVID-19 epidemic period, 47% and
0.6% of the CAP hospitalizations had a CCI of 0–1 and ≥5, respec- 
ively ( Table 2 ). The ALOS of CAP hospitalizations was 8.9 days, the 
ercentage of hospitalizations requiring the ICU was 1.8%, and in- 
ospital mortality was 12.4%. Compared with the previous 3 years, 
he distribution of CAP hospitalizations by CCI did not significantly 
iffer; however, significant increases in the percentage of CAP hos- 
italizations requiring ICU and in-hospital mortality were regis- 
ered ( + 51%, 95% CI 1.7–122.83 and + 42%, 95% CI 24.19–64.71, re- 
pectively). No significant differences in the ALOS of CAP hospital- 
zations were observed between the epidemic period and the cor- 
esponding period of the previous 3 years ( Table 2 ). 
Table 3 reports the age, sex, and CCI standardized ratios for 
LOS, hospitalizations requiring ICU, and in-hospital mortality. For 
hese outcomes, the standardized ratios showed no significant dif- 
erence between the observed and the expected results in the pre- 
pidemic period. In the COVID-19 epidemic period, the difference 
etween the observed and the expected ALOS of CAP hospital- 
zations was not significant (SR 1.002, 95% CI 0.97–1.04, P = 0.76). 
lthough the observed CAP hospitalizations requiring ICU were 
igher than expected in the epidemic period, this difference was 
bove the level of significance (SR 1.5, 95% CI 0.95–2.33 P = 0.086). 












































Figure 1. Continued 
Table 1 
Temporal changes in the number of hospitalizations and hospitalization rates for CAP in people aged ≥65 in the Tuscany region during 
the COVID-19 epidemic period (Week 10 to 27, 2020) 
N Hospitalization rate (x 10 0,0 0 0 population) Hospitalization rate changes 
2017-2019 Average 2020 2017-2019 Average 2020 Change (%) 95% CI P value 
Total 2636 1806 278.3 190.7 -31.5 -36; -27 < 0.001 
Sex 
Male 1379 971 335.9 236.5 -29.6 -35; -24 < 0.001 
Female 1258 835 234.5 155.6 -33.6 -39; -27 < 0.001 
Age 
65–74 years 481 335 108.0 75.2 -30.4 -39; -22 < 0.001 
75–84 years 1003 711 292.9 207.6 -29.1 -35; -22 < 0.001 
≥85 years 1152 760 722.8 476.9 -34.0 -40; -28 < 0.001 
CAP: community-acquired pneumonia 
Table 2 
Characteristics and clinical outcomes of CAP hospitalizations during the pre-epidemic (Week 1 to 9, 2020) and epidemic (Week 10 to 27, 2020) periods 
Pre-epidemic period Epidemic period 
2017-2019 2020 Change (%) 95% CI P value 2017-2019 2020 Change (%) 95% CI P value 
Charlson Comorbidity Index (%) 
0–1 47.6 46.1 -3.1 -8.83; 3.03 0.316 45.2 47.0 3.8 -1.6; 9.7 0.171 
2–4 38.6 42.0 8.8 1.6; 16.4 0.016 40.4 40.5 0.1 -5.8; 6.6 0.956 
≥5 11.8 9.4 -20.4 -32.9; -5.3 0.027 11.8 10.6 -10.1 -22.3; 4.2 0.159 
Missing 2.1 2.5 23.2 -14.3; 77.1 0.261 2.6 1.9 -24.9 -47.5; 6.7 0.109 
Average length of stay (days) 8.9 9.1 2.26 -1.6; 6.2 0.262 8.9 8.9 0.2 -3.4; 4.1 0.890 
Hospitalizations requiring ICU (%) 1.6 1.5 -6.9 -41.2; 47.2 0.757 1.2 1.8 51.2 1.7; 122.8 0.041 
In-hospital mortality (%) 10.2 8.6 -15.7 -29.9; 1.0 0.064 8.8 12.5 42.0 24.2; 64.7 < 0.001 
CAP: community-acquired pneumonia; ICU: Intensive Care Unit 
Table 3 
Standardized ratios ∗ for 2020 for ALOS, hospitalizations requiring ICU, and in-hospital mortality of CAP hospitalizations 
Pre-epidemic period Epidemic period 
Standardized ratio ∗ 95% CI P value Standardized ratio ∗ 95% CI P value 
Average length of stay 1.02 0.99; 1.05 0.07 1.002 0.97; 1.04 0.76 
Hospitalizations requiring ICU 0.92 0.77; 1.63 0.55 1.5 0.95; 2.33 0.086 
In-hospital mortality 0.83 0.66; 1.07 0.15 1.44 1.27; 2.31 < 0.001 
ALOS: average length of stay; ICU: Intensive Care Unit; CAP: community-acquired pneumonia 
∗ Ratio standardized for age, sex, and Charlson Comorbidity Index. Standard population: patients hospitalized for CAP in 2017- 
2019 in the two periods 
185 
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Table 4 
CAP Antibiotic consumption (DDD) in the outpatient setting in people aged ≥65 in the Tuscany region 
Pre-epidemic period Epidemic period 
DDD x 10 0 0 population/ day Change 
(%) 
95% 
CI P value 





value 2019 2020 2019 2020 
Overall antibacterial consumptions 26.2 22.8 -13.1 -33; 3 0.026 18.5 12.0 -34.7 -45; -28 0.001 
65–74 23.3 20.4 -12.6 -33; 2 0.032 16.4 10.2 -37.6 -48; -31 0.001 
75–84 26.7 23.1 -13.3 -33; 3 0.025 18.8 12.2 -35.3 -46; -29 0.001 
≥85 33.5 28.9 -13.6 -32; 3 0.019 23.5 16.9 -28.3 -39; -21 0.001 
Penicillins 11.6 10.7 -7.3 -29; 2 0.082 8.8 6.0 -31.9 -45; -29 0.001 
65–74 10.9 10.1 -7.3 -29; 3 0.096 8.3 5.4 -34.0 -47; -31 0.001 
75–84 11.5 10.6 -8.2 -30; 1 0.062 8.8 5.9 -32.5 -45; -29 0.001 
≥85 13.4 12.6 -5.6 -27; 3 0.103 10.2 7.6 -25.9 -40; -23 0.001 
Cephalosporins 4.4 4.1 -5.7 -30; 2 0.075 3.1 2.0 -36.7 -50; -34 0.001 
65–74 3.1 2.9 -4.2 -30; 3 0.101 2.2 1.2 -43.5 -55; -39 0.001 
75–84 4.5 4.3 -4.3 -30; 3 0.091 3.2 2.0 -37.1 -51; -35 0.001 
≥85 7.9 7.2 -8.9 -31; 0 0.045 5.6 4.0 -28.6 -43; -27 0.001 
Fluoroquinolones 5.6 3.6 -35.3 -47; -23 0.001 3.6 2.5 -30.7 -40; -21 0.001 
65–74 4.8 3.1 -35.6 -48; -23 0.001 3.0 2.0 -33.5 -42; -23 0.001 
75–84 6.0 3.9 -34.5 -47; -22 0.001 3.8 2.6 -31.6 -40; -22 0.001 
≥85 7.2 4.6 -36.2 -48; -25 0.001 4.5 3.5 -23.8 -33; -13 0.001 
Macrolides 4.7 4.3 -7.5 -28; 7 0.201 3.0 1.6 -46.0 -56; -39 0.001 
65–74 4.5 4.2 -6.6 -29; 6 0.175 2.9 1.5 -47.5 -58; -41 0.001 
75–84 4.7 4.3 -7.3 -27; 8 0.231 3.0 1.6 -46.5 -55; -38 0.001 
≥85 5.1 4.5 -10.3 -25; 8 0.247 3.2 1.9 -41.6 -50; -32 0.001 













































































astly, the observed in-hospital mortality of CAP hospitalizations 
uring the epidemic period was significantly higher than expected 
SR 1.44, 95% CI 1.27–2.31, P < 0.001). 
Table 4 reports data concerning CAP antibiotic consumption in 
he outpatient setting in people aged ≥65 in the Tuscany region. 
he percentage change in the dispensed DDD for all the selected 
ntibacterial drugs for the treatment of CAP from 2019 to 2020 was 
13.1% (95% CI -29%, + 3%) in the COVID-19 pre-epidemic period 
nd -34.7% (95% CI -43%, -25%) in the COVID-19 epidemic period. 
uring the COVID-19 pre-epidemic period, only fluoroquinolones 
howed a significant decrease in the dispensed DDD compared 
ith the previous year (percentage change: -35.3%; 95% CI -47%, 
23%). Conversely, during the COVID-19 epidemic period, all the se- 
ected antibacterial drugs showed a significant decrease in the dis- 
ensed DDD compared with the previous year; fluoroquinolones 
nd macrolides showed the minimum and maximum reductions, 
espectively (percentage changes: -30.7%; 95% CI -40%, -21% and - 
6%; 95% CI -56%, -39%, respectively). 
iscussion 
Our study aimed to evaluate the secondary impact of large- 
cale containment measures for SARS-CoV-2 on the incidence of 
AP in older people during the first wave of COVID-19 in the Tus- 
any region (February–July 2020). To assess the impact on the in- 
idence of CAP in older people, hospital admissions with a pri- 
ary diagnosis of CAP occurring in all the hospitals in the Tuscany 
ealthcare system were evaluated and compared with the average 
f the previous 3 years. In addition, the average hospital length 
f stay, hospitalizations requiring ICU, and in-hospital mortality of 
atients admitted with CAP were assessed to evaluate differences 
n the characteristics and severity of the CAP hospitalizations. Fur- 
hermore, changes in the consumption of antibacterials (dispensed 
DD) indicated for the treatment of CAP were evaluated as a proxy 
or less severe CAP cases occurring in the outpatient setting. Re- 
ults of the study highlighted a significant reduction of the hospi- 
alization rates for CAP during the epidemic period in the Tuscany 
egion, compared with the average of the previous 3 years. The ob- 
erved reduction of hospitalization rates during the epidemic pe- 
iod was similar between sexes and among different age groups. 
urthermore, in-hospital mortality for CAP was significantly higher 186 n the epidemic period than expected from previous years. Lastly, 
onsistent reduction of consumption across all antibacterial classes 
ndicated to treat CAP were observed in the outpatient settings 
uring the epidemic period. 
These findings suggest a significant and generalized reduction 
f CAP in older people during the COVID-19 epidemic period. The 
ost plausible explanation for this reduction is the interruption of 
erson-to-person transmission of CAP pathogens due to the effec- 
iveness of containment measures to curb the COVID-19 pandemic. 
ndeed, the timing for implementation of these measures coincided 
ith a significant reduction in the hospitalization rate for CAP, i.e., 
he first national containment measures such as school and uni- 
ersity closures and movement restrictions occurred in the same 
eek in which the first significant negative deviation in the trend 
f CAP hospitalization rates was observed. Interestingly, the signif- 
cant deviation from previous years in the hospitalization rate for 
AP remained even after the lift of the national lockdown until the 
nd of the first wave of the COVID-19 epidemic in July. These re- 
ults may indicate that prevention measures that remained manda- 
ory after the lift of the national lockdown—namely, the physical 
istancing rules and obligation to wear a face mask when leaving 
ome—may have played a role in reducing CAP incidence. 
It should be noted that—especially in the first phases of the 
OVID-19 outbreak—the reduction of CAP hospitalizations in older 
eople may have been influenced by a shift of the provision of 
are for less severe cases to the outpatient setting. Indeed, it is 
lausible that less severe patients, with or without consultation 
ith their physicians, decided to defer or avoid seeking hospi- 
al care during the pandemic ( Birkmeyer et al., 2020 ; Lu et al.,
007 ). However, if less seriously ill patients were disproportion- 
tely treated in the outpatient setting during the COVID-19 pan- 
emic, an increase in antibacterial consumption would have been 
xpected instead of the relevant and significant decrease observed. 
herefore, if cases had shifted from the hospital to the outpatient 
etting, it was minimal and appeared to have been largely out- 
tripped by the overall reduction in CAP cases . However, as most 
f the CAP antibacterials would also be used for bronchitis and 
cute exacerbations of chronic obstructive pulmonary disease, the 
bserved reduction in consumption is also consistent with an over- 
ll reduced rate of lower respiratory tract infections in the com- 
unity rather than CAP specifically. In light of this, it is reason- 























































































































ble to speculate that containment measures may have benefi- 
ially reduced the transmission of other, non-pandemic infections 
nd that the respiratory infection burden is likely to increase as 
OVID-19 containment measures are lifted. Indeed, this hypothe- 
is is confirmed by preliminary findings from infection surveillance 
tudies reporting a significant decrease of circulation of respiratory 
athogens, such as seasonal influenza, Streptococcus pneumonia and 
aemophilus influenza , following the introduction of COVID-19 con- 
ainment strategies and public health campaigns ( Chiu et al., 2020 ; 
rueggemann et al., 2021 ; Sakamoto et al., 2020 ). 
The increased in-hospital mortality rate in patients hospital- 
zed for CAP during the epidemic period cannot be ascribed to 
he lack of available resources to manage critical patients due to 
OVID-19 because the TPHCS never experienced a lack of availabil- 
ty of ICU beds. However, it may be due to patients staying away 
rom hospitals for fear of contagion. Indeed, during the COVID-19 
andemic, people—especially older people—may have been weigh- 
ng the risks of seeking out medical care against potentially con- 
racting SARS-CoV-2; these concerns of contagion may have in- 
reased the in-hospital mortality rate for 2 different but interre- 
ated reasons. First, less seriously ill patients disproportionately 
tay away from the hospital compared with more severely ill pa- 
ients. Second, patients who delay seeking care put themselves at 
isk of serious complications and are eventually admitted to hos- 
ital with more severe illness ( De rosa et al. , 2020 ; Hafner 2020 ;
olomon et al., 2020 ). If related to a delay in seeking care, the find-
ng of increased in-hospital mortality highlights the need to en- 
ure that patients with CAP requiring hospital care obtain it dur- 
ng a pandemic. Another possible explanation for the increased in- 
ospital mortality rate is that a disproportionate reduction in CAP 
aused by pathogens associated with lower mortality and compli- 
ation occurred, e.g., a reduction in the rate of viral CAP compared 
ith bacterial CAP. However, further studies evaluating the rate of 
AP by type of pathogen are needed to confirm this hypothesis. 
During a pandemic, decisions should be made to balance the 
emands of responding directly to the pandemic with simulta- 
eously engaging in strategic planning and coordinated action to 
aintain essential health service delivery, mitigating the risk of 
ystem collapse. The described indirect impact of pandemic con- 
ainment measures on respiratory tract infections provides use- 
ul information for health services planning and provision dur- 
ng the pandemic. In particular, the findings of a reduced CAP 
ospital caseload may be useful to guide strategies for optimiz- 
ng health workforce capacity across health services. Indeed, dur- 
ng pandemics, health systems face predictable health workforce 
hallenges, including the redistribution of staff to treat increasing 
umbers of pandemic patients and the loss of staff who may be 
uarantined or infected. Furthermore, the described potential for 
elay in seeking care for fear of contagion suggests the need to 
trengthen primary care support, to implement adaptive responses 
e.g., teleconsultation, integrated primary care, clear referral path- 
ays) and ensure public awareness and sustainability of health ser- 
ices for CAP patients. 
The present study has several strengths and limitations. A 
trength of the study is that the sample represents virtually the 
hole population of an administrative region with approximately 
.7 million inhabitants and a wide and varied geographical area. 
n particular, the data analyzed could be considered representative 
f all the hospital care that has been provided to the study pop- 
lation as the regional public health system provides healthcare 
ree of charge for the entire population and private providers play 
 minimal role, especially in the provision of acute hospital care 
 Lastrucci et al., 2018 ). Similarly, data of antibacterial consump- 
ion in the outpatient setting could be considered representative 
f the overall consumption of Tuscany inhabitants, as the purchase 
f antibacterials requires a registered prescription from the gen- 187 ral practitioner. Lastly, the study adopted covered a period that 
ncluded the whole of the first wave of SARS-CoV-2, which allowed 
omparison between CAP incidence and the SARS-CoV-2 epidemic 
ituation and related containment measures. The present study has 
ome limitations. First, although results showed a close association 
etween containment measures and a decrease in CAP, the study 
esign does not allow us to assure the causality link between the 
wo phenomena. Second, it was not possible to establish the in- 
ependent effect of each of the individual containment measures 
s these were implemented almost simultaneously in the region. 
hird, although the study results accurately represent the hospi- 
alization rate for CAP in the older population, it was not possi- 
le to accurately measure the total incidence of CAP in the region 
s less severe cases treated exclusively in the outpatient setting 
re not registered in the regional information system. The outpa- 
ient consumption of antibacterial drugs for CAP may be consid- 
red as a proxy for the incidence of CAP in the outpatient setting 
nly to a limited extent. Nevertheless, it should be underlined that 
ntibacterial consumption in the outpatient setting allowed us to 
onsider CAP cases for both bacterial and viral pathogens. Indeed, 
mpiric antibacterial treatments in the outpatient setting are rec- 
mmended in almost all the patients with CAP because bacterial 
athogens often coexist with viruses, and the current diagnostic 
ests are not accurate or fast enough to ascertain whether CAP is 
ue solely to a virus at the time of presentation ( Metlay et al.,
019 ). Lastly, as the study was based on routinely collected ad- 
inistrative data, it was not possible to control the quality of the 
ase determination (i.e., the accuracy in case coding). However, the 
uality of TPHCS administrative data is very high in terms of accu- 
acy and reliability because the data are audited each year. 
onclusion 
In conclusion, significant decreases in the hospitalization rate 
nd the outpatient consumption of antibacterials for CAP were 
bserved in the older population during the first wave of the 
OVID-19 pandemic. The timing of these decreases largely coin- 
ided with the timing of implementation of initial epidemic con- 
ainment measures. These findings suggest that the potential ben- 
fits of pandemic containment measures can extend beyond the 
revention of COVID-19 to include reducing the burden of respira- 
ory infectious diseases. Furthermore, results showed a significant 
ncrease in in-hospital mortality in patients hospitalized for CAP 
uring the pandemic; such increases may be linked to a delay in 
eeking care by patients who are afraid of contracting SARS-CoV- 
 in healthcare settings; thus, effort s should be made to ensure 
hat patients can obtain required hospital care during a pandemic. 
he above-described indirect effects of SARS-CoV-2 containment 
easures have major implications for health services planning and 
rovision during pandemics. Further studies are needed to confirm 
nd characterize these indirect effects of SARS-CoV-2 containment 
easures on CAP in the older population and to clarify better the 
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